Yet another valuation sign-post in the world of later-stage deals. And this time the currency is geography.
In May 2003, two months after GW Pharmaceuticals PLC submitted cannabis-based medicinal extract (Sativex) for approval in the UK,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?